WO2019098568A2 - Composition de soulagement, prévention ou traitement de la douleur comprenant un extrait de camellia japonica - Google Patents

Composition de soulagement, prévention ou traitement de la douleur comprenant un extrait de camellia japonica Download PDF

Info

Publication number
WO2019098568A2
WO2019098568A2 PCT/KR2018/012925 KR2018012925W WO2019098568A2 WO 2019098568 A2 WO2019098568 A2 WO 2019098568A2 KR 2018012925 W KR2018012925 W KR 2018012925W WO 2019098568 A2 WO2019098568 A2 WO 2019098568A2
Authority
WO
WIPO (PCT)
Prior art keywords
pain
camellia
extract
composition
alleviating
Prior art date
Application number
PCT/KR2018/012925
Other languages
English (en)
Korean (ko)
Other versions
WO2019098568A3 (fr
Inventor
김윤태
김재구
임은영
심재원
김민정
이창호
조승목
Original Assignee
한국식품연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국식품연구원 filed Critical 한국식품연구원
Publication of WO2019098568A2 publication Critical patent/WO2019098568A2/fr
Publication of WO2019098568A3 publication Critical patent/WO2019098568A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Definitions

  • the present invention was made by the task number E0164502-02 under the support of the Ministry of Science, Technology & Information and Communications of the Republic of Korea.
  • the research institute of the above subject is Korea Food Research Institute, the research project name is "Korea Food Research Institute major project”
  • the research period is 2016. 01. ⁇ 2021. December 31, the contribution rate is 1/1.
  • the present invention relates to a composition for alleviating, preventing or treating pain comprising a camellia extract.
  • Camellia japonica L. Camellia japonica L.
  • Camelliae Camelliae
  • Jeonnam area occupies about 67% of the total planted area.
  • the inventors of the present invention have made efforts to develop a safe material for human body which can relieve pain effectively, particularly plant-derived materials. As a result, it has been found out that the extract of Camelliaceae is very effective for alleviating, Thereby completing the invention.
  • Another object of the present invention is to provide a method for alleviating, preventing or treating pain, comprising the step of administering to a subject in need thereof an effective amount of alleviating, preventing or treating pain of the camellia extract.
  • the present invention relates to a pharmaceutical composition for relieving, preventing or treating pain comprising Camellia japonica L. extract.
  • the camellia extract according to the present invention comprises a solvent extract of camellia and a solvent fraction thereof, Camellia extracts exhibit relief, preventive and therapeutic effects against pain.
  • the present inventors have made extensive efforts to develop a safe material for humans, particularly plant-derived materials, which can relieve pain effectively, and as a result, it has been found that the extract of Camelliaceae is very effective for alleviating, preventing or treating pain.
  • Camellia japonica L. belongs to the genus Camellia. It is an arboreous tree with evergreen evergreen trees. It blooms from winter to early spring. Seeds are harvested at the end of October and contain 3-5 seeds per plant. Leaves are alternate oval or long oval with wavy sawtooth on edge. The surface is dark green with shine and the back side is yellowish green with no hairs and thick. It is reported that about 200 species are distributed in Asian region. One of them ( Camellia japonica L.) is native to Korea, and Camellia species, which are distributed in relatively cold places, are emphasized as genetic resources.
  • Camellia has been mainly used as a source of horticultural material since the past, and its main ingredients are saturated fatty acids (9.1-11.5%), oleic acid (85.6-89.4%), linoleic acid (1.3-2.9%) and glycerides with high oleic acid It is a clear, non-drying oil. Its freezing point is low at -25 °C.
  • the extract of camellia japonica leaf is known to be very useful as a natural preservative.
  • One aspect of the present invention relates to a pharmaceutical composition for alleviating, preventing or treating pain comprising a camellia extract.
  • the camellia may be at least one selected from the group consisting of fruits, roots, stems and leaves of a camellia, and may be, for example, a camellia leaf.
  • the camellia extract may be an extract obtained by extracting a camellia tree with a polar solvent, a non-polar solvent or a mixed solvent thereof.
  • the polar solvent may be water, alcohol, acetic acid, dimethylformamide (DMFO), dimethyl sulfoxide (DMSO), or a mixture thereof, but is not limited thereto.
  • the alcohol may be a linear or branched alcohol having 1 to 4 carbon atoms such as methanol, ethanol, propanol, butanol, n-propanol, iso-propanol, n-butanol, 1-pentanol, 2-butoxyethanol, Glycols, or mixtures thereof, but is not limited thereto.
  • the solvent is used in an amount of 10% or more to less than 100% (v / v), 20% to less than 100% (v / (V / v), less than 100% (v / v), less than 100% (v / v) Or a linear or branched alcohol aqueous solution having from 1 to 4 carbon atoms and less than 100% (v / v), and may be, for example, an aqueous 70% (v / v) alcohol solution.
  • the nonpolar solvent may be selected from the group consisting of acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, Chlorobenzene, benzene, diethyl ether, diethylsulfide, chloroform, dichloromethane, dichloromethane, dichloromethane, chloroform, Diethylamine, ether, carbon tetrachloride, tetrahydrofuran or a mixture thereof, preferably acetone, ethyl acetate, chloroform, butyl acetate, 1,3-butylene glycol , Hexane, diethyl ether, or a mixture thereof, but is not limited thereto.
  • the camellia extract is a camellia tree extract obtained by using ethanol as a solvent.
  • the camellia extract is a camellia leaf extract obtained by extracting ethanol with a solvent.
  • the 'extract' includes a solvent crude extract, a specific solvent soluble extract (solvent fraction) and a solvent fraction of a solvent crude extract.
  • extract as used herein means a crude extract in the art as described above, but broadly includes fractions obtained by further fractionating the extract.
  • the Camellia sinensis extract is obtained not only by using the above-mentioned extraction solvent but also by additionally applying a purification process thereto.
  • a fraction obtained by passing the above extract through an ultrafiltration membrane having a constant molecular weight cut-off value, and a separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) is also included in the camellia extract of the present invention.
  • camellia extract used in the present invention can be prepared in a concentrate and / or powder state by an additional process such as vacuum distillation and freeze drying or spray drying.
  • the present invention includes an extract extracted from a camellia tree which is a natural plant material, there is no adverse effect on the human body even when administered in an excessive amount. Therefore, the quantitative upper limit of the camellia extract contained in the composition of the present invention can be selected by a person skilled in the art have.
  • composition of the present invention is very effective for alleviating, preventing or treating pain.
  • composition of the present invention exhibits remarkable pain relieving effect not only by intravenous injection or skin application but also by oral administration.
  • the composition of the present invention having such characteristics can be applied to foods well.
  • composition of the present invention not only alleviates and treats the pain generated, but also has an effect of preventing pain when administered to a subject before pain occurs.
  • &quot pain " is used in the present invention in its broadest sense and includes acute and chronic pain such as pain ache and pain, such as somatic pain and visceral pain; Pain, pain, inflammatory pain, dysfunctional pain, idiopathic pain, superficial pain, deep pain, itching, neuropathic pain such as centrally generated pain and peripherally generated pain, migraine, and cancer pain.
  • &quot nociceptive pain " refers to any pain caused by a noxious stimulus that is potentially damaging or actually damaging to body tissues.
  • the painful water-soluble pain includes, without limitation, pain caused by ben, cut, bruise, bone fracture, crush injury, burn and similar wounds. Pain receptors for tissue damage (nociceptors) are mostly located in the skin, musculoskeletal or internal organs.
  • Acupuncture pain occurs in response to activation of nociceptors by a specific subset of peripheral sensory neurons, that is, intense or harmful stimuli.
  • Acute water-soluble pain is a generally sensitive, self-limiting, and provides a biological function of protection by acting as a warning of potential or ongoing tissue damage.
  • Pain Acceptable pain is typically very limited to locality. Examples of painful painful pain include, but are not limited to, traumatic or surgical pain, labor pain, sprains, bone fractures, burns, bumps, but are not limited to, bruises, injections, dental procedures, skin biopsies and obstructions.
  • &quot somatic pain " refers to pain occurring in bones, joints, muscles, skin or connective tissue. This type of pain is typically very localized.
  • &quot visceral pain " is used herein to refer to any or all of the organs such as respiratory, gastrointestinal tract and pancreas, urinary tract and reproductive organs, Used to indicate pain that occurs.
  • Embolic pain includes pain induced by tumor involvement of the organ capsule.
  • Other types of visceral pain are typically caused by occlusion of the hollow viscus, characterized by intermittent cramping and severe local pain.
  • Embolic pain may be associated with inflammation, as in the case of cystitis or reflux esophagitis.
  • &quot inflammatory pain " refers to pain associated with active inflammation, which may be caused by trauma, surgery, infection, and autoimmune disease.
  • Inflammatory pain is associated with joints such as postoperative, post-traumatic pain, arthritis (rheumatoid or osteoarthritis) pain, and axial low back pain. ), Pain associated with damage to muscles and tendons, or pain when there is a tissue injury or inflammation.
  • &quot superficial pain " refers to a pain sensed by a skin segment in which a dorsal root nerve is distributed, and refers to a direct pain sensation at the point where stimulation is felt.
  • &quot deep pain " refers to pain originating from deep organs, which varies in character and degree depending on the nature of the tissue. Particularly sensitive areas of pain are tendons, perineum, ligaments, joints, periosteum, blood vessels and nerves. In general, deep pain is dull, spreads around, and feels wide. Pain in the deep or intestine is complicated in its mechanism, making it difficult to locate the pain rather than the surface pain, and problems such as nausea, sweating, and elevated blood pressure also appear.
  • &quot neuropathic pain " as used herein refers to pain resulting from the sensory input of abnormal processing by the peripheral or central nervous system resulting from disturbance of the peripheral or central nervous system.
  • neuropathic pain Pain In contrast to water-soluble pain, neuropathic pain is depicted as actual “burning,” “electric,” “tingling,” or “shooting” do. Neuropathic pain is often defined as chronic allodynia (defined as pain due to stimuli that do not cause a normal pain response, such as a mild touch) and hyperalgesia (a high susceptibility to normal pain stimuli ). It can last for months or years after apparent healing of any damaged tissue.
  • &quot procedural pain " refers to pain that occurs in internal medicine, dentistry, or surgery. The procedure is usually scheduled or associated with acute trauma.
  • &quot itch &quot
  • itch &quot is used herein in its broadest sense and refers to all types of itchy, stinging sensations of acute intermittency and persistence that can be generally described by limiting to local.
  • the itch may be due to idiopathic, allergic, metabolic, infectious, drug-induced, liver, kidney disease or by cancer. "Pruritus” is severe itching.
  • the term " palliative " means any action in which pain is suppressed or delayed by administration of the composition.
  • prevention means any action in which pain is suppressed or delayed due to administration of the composition in advance of the possibility of pain occurring.
  • treatment means any action in which the development of pain is suppressed, pain relieved, or pain relieved by the administration of the composition.
  • the composition of the present invention has the effect of alleviating, preventing or treating pain in various models of painful pain.
  • the painful animal model is selected from the group consisting of a skin incision model, a neural branch ligation injury model, a complete Freund's adjuvant induced inflammatory pain model, a chemotherapy induced peripheral neuropathic pain model, Pain models, and the like.
  • the nerve ligated in the neural branch ligation injury model is a total peroneal nerve and / or tibial nerve.
  • the chemical agent to be administered in the preparation of the chemotherapy-induced peripheral neuropathic pain model is an anticancer agent, specifically, but not limited to, vincristine, paclitaxel, and the like.
  • the pain sensed by the animal pain model may be quantified by von frey filament test or ultrasound vocalization calls measurements.
  • the composition of the present invention has pain relief, prophylactic or therapeutic effects in an in vitro pain cell model.
  • the in vitro pain cell model is a cell model expressing CCR2 (chemokine receptor type 2).
  • the cells may be HEK cells (Human embryonic kidney cells 293), but are not limited thereto.
  • the measurement of pain in the in vitro cell model can be carried out by treating a Camellia sinensis leaf extract, which is an effective ingredient of the composition of the present invention, with CCR2-expressing cells, followed by treatment with CCR2's monocyte chemoattractant protein 1 (MCP-1) or CCL2 CC motif chemokine ligand 2) and measuring changes in intracellular calcium concentration.
  • a Camellia sinensis leaf extract which is an effective ingredient of the composition of the present invention
  • the content of the camellia extract in the composition according to the present invention can be appropriately adjusted depending on the mode and purpose of use, patient condition, symptom type, and the like, and is 0.1 to 99.9% by weight, 0.1 to 99.0% by weight, 0.1 To 90.0% by weight, 0.1 to 80.0% by weight, 0.1 to 70.0% by weight, 0.1 to 60.0% by weight, preferably 0.1 to 50% by weight.
  • compositions according to the present invention can be administered to mammals, including humans, in a variety of routes.
  • the mode of administration may be any conventional manner and may be administered, for example, by oral, skin, intravenous, intramuscular, subcutaneous, and the like routes, preferably orally.
  • composition of the present invention may be formulated into oral formulations such as powders, granules, tablets, capsules, ointments, suspensions, emulsions, syrups and aerosols, or parenteral formulations such as transdermal preparations, suppositories, And the like.
  • composition of the present invention may contain pharmaceutically acceptable and physiologically acceptable carriers, excipients and diluents as well as adjuvants such as the camellia extract.
  • Examples of carriers, excipients and diluents that can be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used can be used.
  • Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose sucrose), lactose, gelatin, and the like.
  • lubricants such as magnesium stearate talc may also be used.
  • agent for oral administration examples include suspensions, solutions, emulsions, syrups, ointments and the like.
  • excipients such as wetting agents, sweeteners, fragrances and preservatives are included in addition to water and liquid paraffin which are commonly used simple diluents .
  • Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, transdermal preparations and the like.
  • the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like.
  • suppository preparation witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like can be used.
  • composition comprising the camellia extract of the present invention may be administered alone, but is generally selected in consideration of the mode of administration and standard phamaceutical practice May be administered in admixture with a pharmaceutical carrier.
  • a composition containing the camellia extract of the present invention may be in the form of tablets containing starch or lactose, in the form of capsules containing the active ingredient alone or as an excipient, or in the form of capsules containing flavoring or coloring chemicals Orally, sublingually or sublingually in the form of tablets, dragees, troches,
  • Such liquid preparations may contain suspending agents, for example, a mixture of semisynthetic glycerides such as methylcellulose, withexol, or apricot kernel oil with a PEG-6 ester, or a mixture of PEG-8 and caprylic / capric glyceride ≪ / RTI > such as a mixture of glycerides, such as a mixture.
  • the dose of the composition containing the camellia extract of the present invention may be varied depending on the age, weight, sex, dosage form, health condition and disease level of the patient. It may be administered in divided doses.
  • the above-mentioned dosage is exemplified as an average case, and the dose may be increased or decreased depending on individual differences.
  • Another aspect of the present invention relates to a food composition for alleviating or preventing pain comprising a camellia extract.
  • the food composition can be variously used for foods for relieving or preventing pain.
  • Examples of the food to which the extract of the present invention can be added include various foods such as beverage, gum, tea, vitamin complex, leavening tea and health food, and health food such as powder, granule, tablet and capsule Can be used.
  • the content of the camellia extract contained in the food composition is not particularly limited depending on the form of the food, the intended use, etc., and may be, for example, 0.01 to 15% by weight of the total food, May be added at a ratio of 0.02 to 10 g, preferably 0.3 to 1 g based on 100 mL.
  • the food composition of the present invention contains the above-mentioned Camellia sinensis extract as an essential ingredient in the indicated ratio, and there is no particular limitation on the liquid ingredient.
  • the food composition may contain various flavors or natural carbohydrates, have.
  • natural carbohydrates examples include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like And sugar alcohols such as xylitol, sorbitol and erythritol.
  • Natural flavors tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above .
  • the food composition of the present invention can be used as a flavoring agent such as a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, A salt thereof, an organic acid, a protective colloid thickener, a pH adjusting agent, a stabilizer, a preservative, a glycerin, an alcohol, a carbonating agent used in a carbonated drink, and the like.
  • the compositions of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The ratio of such additives is not critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
  • the food composition of the present invention when prepared as a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, Can be included.
  • Another aspect of the present invention relates to a method for alleviating, preventing or treating pain comprising administering to a subject in need thereof an effective amount of alleviating, preventing or treating pain of a camellia extract.
  • the method of the present invention utilizes the camellia extract, the common content between the two is omitted in order to avoid the excessive complexity of the present specification.
  • the present invention provides a composition for alleviating, preventing or treating pain comprising a camellia extract.
  • the composition of the present invention not only alleviates and treats the pain generated, but also has an effect of preventing pain when administered to a subject before pain occurs.
  • the composition of the present invention exhibits remarkable pain relieving effect not only by intravenous injection or skin application but also by oral administration, and the composition of the present invention having such characteristics can be applied to foods.
  • FIG. 1 shows the results of a von Frey filament test for the pain sensitivity of the surgical site at 5 and 24 hours after oral administration of Camellia sinica leaf extract to an experimental animal.
  • Fig. 2 shows the result of measuring the number of times of generating ultrasonic waves of the 22-27 kHz lunar power band after oral administration of the camellia leaf extract to the experimental animal and then performing the foot incision surgery at 6 and 24 hours.
  • FIG. 3 shows the results of evaluation of pain sensitivity of the surgical site at 3 days, 6 days, 9 days, 12 days, and 15 days after the daily oral administration of Camellia sinensis leaf extract, .
  • FIG. 4 is a graph showing that the pain sensitivity of the surgical site was measured at 4 hours, 6 hours, 24 hours, 48 hours, and 72 hours after the daily oral administration of Camellia sinensis leaf extract by inducing inflammatory pain by administering CFA to the experimental animals. As shown in Fig.
  • FIG. 5 shows the results obtained by administering vincristine to an experimental animal to induce peripheral neuropathic pain and administering a daily oral administration of the extract of Camelliaceae to the mice at 6 days, 7 days, 8 days, 11 days, 14 days, and 17 days
  • the pain sensitivity at the postoperative site was measured by mechanical allodynia evaluation.
  • FIG. 6 shows the results of oral administration of the extract of Camellia yambenius L. on a daily basis from day 7 to day 13 after induction of peripheral neuropathic pain by administering paclitaxel to the experimental animals. Then, on days 6, 7, 8, 11 Day and 13 days after surgery, using mechanical allodynia evaluation.
  • FIG. 7 shows the results of measurement of mechanical sensitivity of the surgical site after 0 day and 12 days after the daily oral administration of Camellia sinensis leaf extract and diabetic induction neuropathic pain by administering STZ to experimental animals, to be.
  • Fig. 8 shows the result of measuring the intracellular calcium concentration after treating CCR2 expressing cell line with Camellia sinensis leaf extract.
  • the sample of Camellia sinensis leaf was dried by hot air, and 70 vol% of grain alcohol was added 10 times (v / v) per 100 g of raw material. After extraction at 80 °C for 4 hours, the filtrate and residue extract were combined and filtered and concentrated under reduced pressure. All the extracts were filtered and concentrated under reduced pressure, lyophilized and powdered for use in the experiment.
  • Sprague-Dawley (SD) rats 200-250 g, male
  • C57Bl / 6 mice (21-26 g, male) were purchased from Samtako Co., Respectively.
  • the animals were fed under the conditions of temperature 22 ⁇ 1 °C, humidity 55 ⁇ 5%, day and night cycle (12 hours day / 12 hours night), illumination 300 lux, feed and water free. All animals were managed by the KFRI-IACUC (National Food Research Institute, Laboratory Animal Care and Use Committee) guidelines.
  • the 70% ethanol extract of Camellia sinensis was prepared by dissolving and suspending the extract in the second distilled water at an appropriate concentration.
  • the prepared samples were orally administered at a dose of 300 mg / kg / 5 ml for rats and orally at a dose of 200 mg / kg / 10 ml for mice.
  • the control group was orally administered the same amount of secondary distilled water.
  • a rat skin incision model was proposed by Brennan [Brennan et al. Pain 64: 493-501 (1996). Generally, postoperative pain is thought to be a form of acute pain, and the incision model of the rat is thought to be similar to the postoperative pain state in humans.
  • the nerve branch ligation impaired animal model was proposed by Decosterd and Woolf [Decosterd & Woolf Pain 87: 149-158 (2000)].
  • CFA is an antigen solution which is inactivated by heat treatment and then emulsified in dried oil / saline (1: 1) at a concentration of 0.5 mg / kg.
  • the CFA-induced inflammatory pain model cited Sotocinal's method [D. De Rantere et al. Eur J Pain 20 (3): 417-426 (2016)].
  • CFA treatment was performed after general anesthesia using an inhalation anesthesia device with isoflurane solution.
  • CFA (Sigma-Aldrich Korea) solution was diluted 50% with physiological saline and subcutaneously injected 150 ⁇ l under the skin 6 mm below the left footpad of the rat. The injected CFA solution was pressed to prevent counting, and when awakened from anesthesia, it was transferred to a breeding cage to recover.
  • Cyclophosphamide was induced by intraperitoneal injection of vincristine 150 ⁇ g / kg, paclitaxel 2 mg / kg once daily for 7 days, and von Frey test was used.
  • mice fasted for 4 hours were allowed to induce STZ sodium citrate solution to 7.5 mg / ml, followed by intraperitoneal administration for 5 consecutive days at a dose of 50 mg / kg.
  • Diabetic animal models were identified by measuring fasting blood glucose after fasting for 12 hours.
  • the average fasting blood glucose level of the animal model of diabetes mellitus was 450 mg / dl, which was significantly higher than the mean fasting blood glucose of 95 mg / dl of the mouse without diabetes induction.
  • HEK cells expressing CCR2 were seeded in a black 96 well plate at a concentration of 1 ⁇ 10 4 cells / mL and cultured overnight.
  • Cells were washed once with HEPES (4- (2-Hydroxyethyl) piperazine-1-ethanesulfonic acid) buffer and treated with Fura-2 am 5 ⁇ M for 30 min.
  • HEPES 4- (2-Hydroxyethyl) piperazine-1-ethanesulfonic acid
  • Fura-2 am 5 ⁇ M for 30 min.
  • Camellia sinica leaf extract was treated at a concentration of 10 ⁇ g / ml and then cultured for 30 minutes.
  • the 96-well plate was transferred to a fluorescence microscope and treated with MCP-1 (monocyte chemoattractant protein 1), a ligand for CCR2 at 15 seconds, and the intracellular calcium concentration was measured for 2 minutes 30 seconds.
  • MCP-1 monocyte chemoattractant protein 1
  • a ligand for CCR2 a ligand for CCR2
  • the ratio of the change when the MCP-1 was treated to the control group containing the HEPES buffer was set to 1.
  • the rats were placed in an acrylic box mounted on a wire mesh test bench with a mesh size of 2 x 2 mm and adapted for at least 15 minutes.
  • the pain threshold value (g) was evaluated by using a continuous fleece filament (Stoelting, USA).
  • the filament is contacted vertically on the left footpad and maintained for 5-6 seconds, and the rat is regarded as showing a positive avoidance reaction or showing a positive response if it immediately flaps or licks the foot as the hairs are released.
  • stimulated from the main prefilament in the central part it was stimulated with a weak filament if it showed a positive reaction, and stimulated with a strong filament if there was no positive reaction.
  • the minimum stimulation size for positive reaction was the threshold value, and the upper limit was not applied when there was no reaction even at 15 g or more.
  • CFA Complete Freund ⁇ s Adjuvant
  • Induced Inflammatory Pain Model and Chemotherapy In the induced peripheral neuropathic pain model, the pressure was applied to the central part of the hindpaw of the experimental animal.
  • Rats produce ultrasound when they are in pain, pain, atrophy, and stress, and their ultrasound range is reported to be 22-27 KHz (Portfors CV J Am Assoc Lab Anim. Sci. 46 (1): 28-34 )).
  • the rats were exposed to ultrasound (22-27) using a USV measurement system (Sonotrack®, ver 1.5.0, Metris, Netherlands) KHz) were measured.
  • the rats were placed in an acrylic box capable of measuring ultrasound, stabilized for 15 minutes, and ultrasonic measurement was conducted for 10 minutes.
  • Camellia sinensis leaf extract 30 minutes before skin incision, 300 mg / kg of Camellia sinensis leaf extract was orally administered and mechanical allodynia was evaluated 5 hours after the skin incision operation to measure pain sensitivity at the surgical site.
  • the pain threshold (g) of the control group was 0.700 ⁇ 0.068 (g), while that of the camellia leaf extract 300 mg / kg was 2.175 ⁇ 0.425 (g) Was significantly (p ⁇ 0.01) increased.
  • the results of postoperative Day 1 (POD1) pain threshold were 0.680 ⁇ 0.090 (g) in the control group and 2.825 ⁇ 0.688 (g) in the group treated with 300 mg / kg of camphor leaf extract was significantly (p ⁇ 0.01) increased.
  • the control group was 18.8 ⁇ 4.273 (calls) at 6 hours after surgery, whereas the control group was recorded at 5.125 ⁇ 1.231 (calls) at 300 mg / kg of camphor tree leaf extract (P ⁇ 0.01), respectively.
  • the control group showed 20.1 ⁇ 5.786 (calls), whereas the group treated with 300 mg / kg of camellia japonica leaf extract had a significant (p ⁇ 0.05) It was confirmed that ultrasonic measurement records were reduced.
  • Nerve branching ligation injury The daily doses of Camellia sinica leaf extract 300 mg / kg were orally administered for 15 days after surgery and mechanical allodynia was evaluated to determine pain sensitivity.
  • the pain threshold (g) of the control group was 0.975 ⁇ 0.179 (g), 0.49 ⁇ 0.14 (g), 0.415 (G), 0.13 ⁇ 0.436 (g), 1.743 ⁇ 0.121 (g), and 1.629 ⁇ 0.182 (g) in the group treated with Camellia sinica leaf extract at the concentration of 300 mg / kg g), 2.0 ⁇ 0.338 (g), and 1.371 ⁇ 0.211 (g), respectively.
  • the results showed that Camellia sinensis leaf extract exhibited pain relief in long - term pain model as well as short - term pain model.
  • CFA-induced inflammatory pain model 300 mg / kg of Camellia sinica leaf extract was orally administered daily for 3 days. After 4, 6, 24, 48, and 72 hours of induction, .
  • the pain threshold value (g) of the control group was 7.2 ⁇ 1.02 (g), 5.2 ⁇ 1.2 (g), 3.6 ⁇ 1.13 (g), 4.52 ⁇ 1.382 (g), 6.8 ⁇ 0.8 (g), 8.4 ⁇ 0.748 (g) and 12.2 ⁇ 1.715 (g) in the group treated with 300 mg / kg of Camellia sinensis leaf extract (P ⁇ 0.05), and the intensity of the sensation of pain increased significantly (p ⁇ 0.05).
  • the pain relief effect of Camellia sinica leaf extract was confirmed in the inflammatory pain model.
  • CFA-induced inflammatory pain model A mechanical allodynia evaluation was performed to determine baseline pain between the two groups. As a result, it was confirmed that the preoperative pain threshold value (g) was the same between the two experimental groups.
  • the chemotherapy induced peripheral neuropathic pain (CIPN) model induced by administration of the anticancer agent vincristine 150 ⁇ g / kg was orally administered at a dose of 300 mg / kg of Camellia sinensis leaf extract daily for 17 days.
  • the von Frey filament test on the 7th day of induction The pain was confirmed.
  • the von Frey filament test was used to observe the pain relief effect until the 17th day.
  • the pain threshold value (g) of the control group was 4.5 ⁇ 1.258 (g) at the last day of vincristine administration and 5.85 ⁇ 1.938 (g) Of the total pain threshold value.
  • the pain threshold (g) of the control group was 3.58 ⁇ 0.943 (g), 4.0 ⁇ 0.816 (g) and 7.5 ⁇ 0.957 (P ⁇ 0.05), the strength of the pain was increased to 8.0 ⁇ 0.816 (g), 10.75 ⁇ 1.493 (g) and 16.5 ⁇ 3.379 (g)
  • the pain relief effect of Camellia sinica leaf extract was confirmed in the chemotherapy induced peripheral neuropathic pain (CIPN) model.
  • CIPN Chemotherapy Induced Peripheral Neuropathic Pain
  • CIPN Peripheral Neuropathic Pain
  • the pain threshold value (g) of the control group was 3.0 ⁇ 1.0 (g) on the last day of administration of paclitaxel, and 2.5 ⁇ 1.5 (g) It was confirmed that there was no difference in the pain threshold values between the groups.
  • the pain threshold (g) of the control group was 1.7 ⁇ 0.3 (g) and 1.2 ⁇ 0.2 (g) 0.1 (g), the intensity of the pain felt was significantly increased (p ⁇ 0.05).
  • the pain relief effect of Camellia sinica leaf extract was confirmed in the chemotherapy induced peripheral neuropathic pain (CIPN) model.
  • CIPN Chemotherapy Induced Peripheral Neuropathic Pain
  • the mean mechanical withdrawal threshold was measured using a von Frey filament test at 0 days before administration of Camellia sinensis leaf extract.
  • the mean value of the mice not inducing diabetes was 2.25 ⁇ 0.445 (g), and the mean pain threshold value of diabetic mice was 0.67 ⁇ 0.16 (g).
  • the pain threshold value was decreased.
  • Camellia sinensis leaf extract was administered once daily for 12 days at a dose of 200 mg / kg. After 12 days, the pain threshold value was 2.26 ⁇ 0.554 (g), which was significantly increased (p ⁇ 0.05) Respectively.
  • the mean fasting blood glucose was measured at the end of the experiment. As a result, it was confirmed that the model of diabetes mellitus was maintained at 440 mg / dl.
  • CCL2 CC motif chemokine ligand 2
  • CCR2 receptor CCR2 receptor
  • the sciatic nerve injury model that induced pain by nerve injury induced pain. Pain was reduced in mice knocked out of CCR2 differently from wildtype. Also, pain was reduced in CCR2 knockout mice in CFA induced inflammatory pain models [Peters & Eisenach, Anesthesiology: The Journal of the American Society of Anesthesiologists, 112 (5), 1250-1258 (2010)].
  • Chemotherapy Induced peripheral neuropathic pain models have also been shown to relieve pain when inhibiting CCL2 / CCR2 signaling [Zhang, H. , et al. The Journal of Pain, 14 (10), 1031-1044. (2013)].
  • the CCR2 antagonist has an effect on various kinds of pain relief, and in the present invention, it was confirmed that the camellia extract was effective as a CCR2 antagonist to alleviate the pain.
  • the Camellia japonica L. leaf extract of the present invention can be used as a pain model animal model, a nerve branch ligation injury model, a CFA induced inflammatory pain model, a chemotherapy induced peripheral neuropathic pain model, a diabetic induction neuropathic pain model , And also confirmed the effect of decreasing calcium concentration, which is a function of CCR2 antagonist, in intracellular experiments. Accordingly, the composition of the present invention containing the extract of Camellia sinensis as an active ingredient exhibits the effect of preventing, alleviating or treating pain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une composition de soulagement, prévention ou traitement de la douleur comprenant un extrait de Camellia japonica en tant que principe actif. La composition de la présente invention présente les effets de non seulement soulager et traiter la douleur générée mais également de prévenir la douleur lorsque cette composition est administrée à un sujet avant que la douleur ne survienne. La composition de la présente invention présente un effet remarquable de soulagement de la douleur non seulement lorsqu'elle est injectée par voie intraveineuse ou appliquée sur la peau mais également administrée par voie orale. La composition de la présente invention possédant de telles caractéristiques peut être appliquée à des aliments.
PCT/KR2018/012925 2017-11-14 2018-10-29 Composition de soulagement, prévention ou traitement de la douleur comprenant un extrait de camellia japonica WO2019098568A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0151554 2017-11-14
KR1020170151554A KR102106325B1 (ko) 2017-11-14 2017-11-14 동백나무 추출물을 포함하는 통증의 완화, 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
WO2019098568A2 true WO2019098568A2 (fr) 2019-05-23
WO2019098568A3 WO2019098568A3 (fr) 2019-07-11

Family

ID=66537838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012925 WO2019098568A2 (fr) 2017-11-14 2018-10-29 Composition de soulagement, prévention ou traitement de la douleur comprenant un extrait de camellia japonica

Country Status (2)

Country Link
KR (1) KR102106325B1 (fr)
WO (1) WO2019098568A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116763851A (zh) * 2020-08-02 2023-09-19 许颢瀚 一种抑制神经元痛感配方

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007108042A1 (ja) * 2006-03-15 2009-07-30 株式会社トロピカルテクノセンター 抗炎症剤
KR100901078B1 (ko) * 2007-10-23 2009-06-03 성균관대학교산학협력단 꽃 추출물을 함유하는 ｓｎａｒｅ 복합체 형성을 억제하기위한 조성물
KR100912140B1 (ko) * 2007-11-07 2009-08-13 건국대학교 산학협력단 동백나무 잎 추출물을 유효성분으로 하는 항 알레르기조성물
KR101326162B1 (ko) * 2009-10-01 2013-11-07 재단법인 제주테크노파크 항염증성 조성물
KR101412057B1 (ko) * 2012-07-04 2014-06-26 배용태 동백나무 추출물을 유효성분으로 함유하는 노화 또는 암 예방 또는 치료용 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116763851A (zh) * 2020-08-02 2023-09-19 许颢瀚 一种抑制神经元痛感配方

Also Published As

Publication number Publication date
KR20190054695A (ko) 2019-05-22
WO2019098568A3 (fr) 2019-07-11
KR102106325B1 (ko) 2020-05-06

Similar Documents

Publication Publication Date Title
WO2016032249A1 (fr) Composition pharmaceutique contenant un extrait de vaccinium bracteatum thunb. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives
KR100523562B1 (ko) 손바닥선인장 추출물 및 이로부터 분리된 화합물을함유하는 신경세포 보호용 조성물
WO2018164325A1 (fr) Composition permettant de soigner les symptômes du syndrome climatère féminin
WO2018208128A1 (fr) Composition pharmaceutique comprenant de la tilianine en tant que principe actif pour le traitement prophylactique ou thérapeutique de la maladie de parkinson
WO2013100340A1 (fr) Composition comprenant un extrait de dendropanax morbiferus pour améliorer la fonction sexuelle masculine
WO2014084616A1 (fr) Composition pharmaceutique contenant un extrait de sceptridium japonicum pour prévenir ou traiter un accident vasculaire cérébral ou des maladies cérébrales dégénératives
WO2015111832A1 (fr) Composition de prévention ou de traitement de maladies liées à la prostate, contenant un extrait de poncirus trifoliata
WO2019098568A2 (fr) Composition de soulagement, prévention ou traitement de la douleur comprenant un extrait de camellia japonica
WO2024181633A1 (fr) Composition pour prévenir, améliorer ou traiter les vergetures comprenant un extrait de corchorus olitorius l et un extrait complexe de taraxacum platycarpum et de hordeum vulgare l
WO2019022482A2 (fr) Composition pour prévenir ou traiter les maladies fibrotiques comprenant un extrait de dendropanax morbifera à titre de principe actif
WO2017183924A1 (fr) Composition pour prévenir ou traiter le syndrome de l'oeil sec comprenant un extrait de feuilles d'érable
WO2016032250A1 (fr) Composition pharmaceutique contenant un extrait de portulaca grandiflora hook. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives
WO2020138834A1 (fr) Composition pour la prévention ou le traitement de maladies de la peau comprenant de la spirée couronne de mariée
KR20150145313A (ko) 감태 추출물을 유효성분으로 포함하는 통증의 완화, 예방 또는 치료용 조성물
KR101500485B1 (ko) 마테 추출물을 유효성분으로 포함하는 통증의 완화, 예방 또는 치료용 조성물
KR101680840B1 (ko) 천궁 추출물을 유효성분으로 포함하는 통증의 완화, 예방 또는 치료용 조성물
WO2016129902A1 (fr) Composition pour prévenir, soulager ou traiter le syndrome d'épuisement professionnel
WO2014157811A1 (fr) Composition pour guérir ou traiter l'arthrite rhumatoïde et l'arthrose
WO2022182199A1 (fr) Composition contenant un extrait à l'eau chaude de cassis pour prévenir, soulager ou traiter les maladies du foie gras non alcooliques
WO2021071321A1 (fr) Composition de prévention ou de traitement de maladie neurodégénératives, contenant un extrait d'un mélange de plantes composé de flos genkwae, de racine de clématite et de rhizome de gastrodia
WO2018106009A1 (fr) Composition comprenant un extrait de feuille d'arbre d'érable ou des fractions de ce dernier destinée à prévenir ou à traiter des maladies oculaires inflammatoires
WO2014157812A1 (fr) Composition pour favoriser la santé d'articulation, ou prévenir, guérir ou traiter l'arthrite rhumatoïde et l'arthrose
WO2011046411A2 (fr) Extraits de marron possédant une activité de protection neurocellulaire et une activité d'inhibition de l'acétylcholinestérase, et leur utilisation
WO2021033995A1 (fr) Composition comprenant un extrait d'amomum tsaoko pour prévenir, atténuer ou traiter une maladie liée à la sarcopénie
WO2020204479A1 (fr) Composition pour soulager des troubles de la circulation veineuse comprenant un extrait de feuille de raisin et un extrait de centella asiatica

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18877362

Country of ref document: EP

Kind code of ref document: A2